ALLK News and Press, Allakos Inc. From 04/11/20

Another biotech IPO has beaten the market blues. Keros Therapeutics (KROS) finished the week up 35%, affirming that the biotech industry won't be deterred by current market volatility. Oncology biotech Keros Therapeutics priced its upsized IPO at the high end to raise $96 million at a $325 m...

SAN FRANCISCO, April 09, 2020 (GLOBE NEWSWIRE) -- Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm.  Further details about the cases can be found at the links provided. ALGN Investo...

SAN FRANCISCO, April 01, 2020 (GLOBE NEWSWIRE) -- Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm.  Further details about the cases can be found at the links provided. AAN Investo...

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Allakos Inc. (“Allakos” or the “Company”) (NASDAQ:ALLK) of the May 11, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed a...

Allakos Reports Encouraging Data for Antolimab Allakos (ALLK) announced that it has received positive response from Phase 1 trial of its lead drug candidate antolimab. Phase 1 trial is an open label study designed to evaluate the lead drug candidate in seven patients suffering from moder...

Allakos (NASDAQ: ALLK ) announces positive results from an open-label Phase 1 clinical trial evaluating lead candidate antolimab in seven patients with moderate-to-severe gastrointestinal symptoms and elevated mast cells associated with mast cell gastrointestinal disease (MGID). More new...

-- Antolimab (AK002) reduced gastrointestinal symptoms by 64 percent in patients with mast cell gastrointestinal disease -- -- Management to host conference call and webcast today at 5:00 pm ET -- REDWOOD CITY, Calif., March 24, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK),...

Phase 3 study of antolimab for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis (previously referred to as eosinophilic gastroenteritis) Phase 2/3 study of antolimab for the treatment of eosinophilic esophagitis Phase 1 study of subcutaneously administered ant...

New York, New York--(Newsfile Corp. - March 20, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Allakos Inc. (NASDAQ: ALLK) ("Allakos" or the "Company") of the May 11, 2020 deadline to seek the role of lead plaintiff in a federal securities ...

SAN FRANCISCO, March 18, 2020 (GLOBE NEWSWIRE) -- Hagens Berman urges Allakos Inc. ( NASDAQ: ALLK ) investors who have suffered significant losses to submit their losses now .  A securities fraud class action has been filed against the Company and certain investors may have valuable...